[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].

Yan Liu, Xiaoyan Ke, Jun Ma, Zhixiang Shen, Xiaohong Zhang, Xin Du, Yiming Zhao, Jing-Qiao Lv, Zhao-min Zhan, Xiao-ying Zeng, Xiaohua Xu, Zesheng LuPubMed 2006

Abstract

Domestic idarubicin is comparable to imported counterpart in efficiency and safety for the treatment of acute leukemia. The most severe side effects of domestic idarubicin is hematological toxicity, which should be closely observed and treated in time, while its non-hematological toxicity is tolerable.
BibTeX
@inproceedings{liu2006multicenter,
  author = {Yan Liu and Xiaoyan Ke and Jun Ma and Zhixiang Shen and Xiaohong Zhang and Xin Du and Yiming Zhao and Jing-Qiao Lv and Zhao-min Zhan and Xiao-ying Zeng and Xiaohua Xu and Zesheng Lu},
  title = {{[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].}},
  booktitle = {PubMed},
  year = {2006},
}

Loading related content...

Figure